Zimmer Partners’s Beta Bionics BBNX Stock Holding History

Zimmer Partners’s Portfolio BBNX Stock Details BBNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$12.2K	–	220
2025 Q1	$12.2K	Buy	+1,000	New	+$18.6K	﹤0.01%	172

Other funds holding BBNX

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Zimmer Partners's BBNX Position: Q2 2025 in Review

Zimmer Partners sold out of Beta Bionics (BBNX) in Q2 2025, closing a stake of 1,000 shares — an estimated $12.2K sold.

Zimmer Partners first reported a position in BBNX in Q1 2025 and held it in 1 quarter. The position peaked at $12.2K in Q1 2025. 116 funds tracked by Wall St. Rank hold BBNX as of Q2 2025.

Zimmer Partners reported no remaining Beta Bionics position as of Q2 2025 after selling out during the quarter.
Zimmer Partners sold 1,000 Beta Bionics shares in Q2 2025, an estimated $12.2K.
Zimmer Partners first reported a position in Beta Bionics in Q1 2025 and held it in 1 quarter.
Zimmer Partners's Beta Bionics position peaked at $12.2K in Q1 2025.
116 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2025.

Based on Zimmer Partners's 13F filing for Q2 2025, filed 14 Aug 2025.